Comparative Pharmacology
Head-to-head clinical analysis: NEOBIOTIC versus PROLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOBIOTIC versus PROLOPRIM.
NEOBIOTIC vs PROLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NEOBIOTIC is a combination antibiotic product containing neomycin (aminoglycoside) and bacitracin (polypeptide antibiotic). Neomycin binds to the 30S ribosomal subunit of bacteria, causing misreading of mRNA and inhibiting protein synthesis. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits.
Inhibits bacterial dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA, RNA, and protein synthesis.
1 g intravenously every 12 hours.
100 mg orally twice daily or 200 mg orally once daily.
None Documented
None Documented
3.5–4.5 hours (terminal) in adults with normal renal function; prolonged to 12–18 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 8-10 hours in normal renal function; prolonged (>20 hours) in significant renal impairment.
Renal: 30–40% unchanged; fecal: 50–60% via biliary elimination; minimal hepatic metabolism.
Primarily renal (80-90% as unchanged drug); less than 5% as metabolites; fecal excretion negligible.
Category C
Category C
Antibiotic
Antibiotic